cvs caremark glp-1 coverage recently announced that Wegovy will become the preferred medication for obesity treatment starting in July, leaving many questions for those currently prescribed Zepbound and other obesity medications. OAC is Well, this is infuriating. π¬,
Description
Research shows GLP-1 receptor agonists effectively reduce visceral fat, though whether this reduction is preferential compared to subcutaneous fat continues to be investigated
This is an individual decision that should be made with full information about both the potential benefits and the real risks
Who May Not Be A Good Candidate For A GLP-1 Add-On
J Clin Endocrinol Metab 98:25532561
Early studies show up to 13% body weight reduction in three months
